Provided by Tiger Trade Technology Pte. Ltd.

Arcus Biosciences Inc.

20.28
-0.9300-4.38%
Post-market: 20.280.00000.00%17:03 EDT
Volume:734.65K
Turnover:15.08M
Market Cap:2.54B
PE:-6.16
High:21.68
Open:21.31
Low:20.24
Close:21.21
52wk High:26.40
52wk Low:6.50
Shares:125.35M
Float Shares:88.65M
Volume Ratio:0.44
T/O Rate:0.83%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2900
EPS(LYR):-3.2900
ROE:-63.26%
ROA:-21.08%
PB:4.03
PE(LYR):-6.16

Loading ...

Cancer drug developer Arcus Biosciences' Q3 net loss widens

Reuters
·
Oct 29, 2025

BRIEF-Arcus Biosciences Q3 Revenue USD 20 Million Vs. IBES Estimate USD 24.6 Million

Reuters
·
Oct 29, 2025

Arcus Biosciences Q3 Operating Income USD -142 Million

THOMSON REUTERS
·
Oct 29, 2025

Truist Financial Sticks to Its Buy Rating for Arcus Biosciences (RCUS)

TIPRANKS
·
Oct 20, 2025

Arcus Biosciences (RCUS) Gets a Hold from Bank of America Securities

TIPRANKS
·
Oct 20, 2025

Taiho exercises option to develop, commercialize casdatifan in Japan, Asia

TIPRANKS
·
Oct 20, 2025

A Fresh Look at Arcus Biosciences (RCUS) Valuation Following Recent Stock Rally

Simply Wall St.
·
Oct 20, 2025

Taiho Pharmaceutical Secures Exclusive License for Casdatifan in Japan and Asia

Reuters
·
Oct 20, 2025

Arcus Biosciences Announces Positive Survival Results from Phase 2 EDGE-Gastric Study of Domvanalimab Plus Zimberelimab in Advanced Gastric Cancer

Reuters
·
Oct 14, 2025

Arcus Biosciences Is Maintained at Buy by Citigroup

Dow Jones
·
Oct 14, 2025

Sector Update: Health Care Stocks Higher Premarket Monday

MT Newswires Live
·
Oct 13, 2025

Gilead Announces Promising Phase 3 Results for Trodelvy in First-Line Metastatic Triple-Negative Breast Cancer and New Data on Domvanalimab Combination in Gastric and Esophageal Cancer

Reuters
·
Oct 13, 2025

Arcus announces first OS results from Arm A1 of Phase 2 EDGE-Gastric study

TIPRANKS
·
Oct 13, 2025

BRIEF-Arcus Bioscience Announces First Overall Survival Results From Phase 2 Edge-Gastric Study

Reuters
·
Oct 13, 2025

Anti-Tigit Domvanalimab Plus Anti-Pd-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 Edge-Gastric Study

THOMSON REUTERS
·
Oct 13, 2025

Arcus Biosciences Inc - No Unexpected Safety Signals Observed in Study

THOMSON REUTERS
·
Oct 13, 2025

Arcus Biosciences reports 267 month median overall survival with domvanalimab zimberelimab and chemotherapy in phase 2 gastric cancer study

Reuters
·
Oct 13, 2025

Arcus Biosciences Announces New Equity Compensation Grants for Employees

Reuters
·
Oct 10, 2025

Arcus Biosciences Inc. COO Jennifer Jarrett Reports Disposal of Common Shares

Reuters
·
Oct 09, 2025

Arcus Biosciences (RCUS) Gets a Buy from Cantor Fitzgerald

TIPRANKS
·
Oct 08, 2025